Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics announced positive results from its Phase 1 COBALT™-LYM trial for CTX130, an allogeneic CAR-T cell therapy targeting CD70, focusing on treating peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). At Dose Level 3 and above, the overall response rate was 70%, with a complete response rate of 30%. The safety profile was favorable, with no dose limiting toxicities reported. The trial involved 19 patients, demonstrating significant clinical benefits and responses across various disease compartments.

Vertex Pharmaceuticals and CRISPR Therapeutics unveiled promising new data on exa-cel for treating transfusion-dependent beta thalassemia and severe sickle cell disease. The study involved 75 patients, with up to 37.2 months of follow-up. Key findings include:

• 42 out of 44 patients with beta thalassemia were transfusion-free post-treatment.
• All 31 patients with sickle cell disease experienced cessation of vaso-occlusive crises.

The safety profile aligns with myeloablative conditioning and stem cell transplant protocols.

CRISPR Therapeutics announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 9:20 a.m. PT. Senior management members will present insights on the company's advancements in gene-based medicines for serious diseases, leveraging the CRISPR/Cas9 technology. A live webcast of the presentation will be accessible on their Investors page, with a replay available for 14 days post-event. CRISPR Therapeutics continues to develop therapies across various sectors, including oncology and rare diseases, collaborating with major partners like Bayer and Vertex Pharmaceuticals.

Vertex Pharmaceuticals and CRISPR Therapeutics announced additional abstracts for the 2022 European Hematology Association (EHA) Congress. The highlight is the late-breaking abstract on the efficacy and safety of exa-cel for beta-thalassemia and sickle cell disease, scheduled for oral presentation on June 12. Three real-world economics abstracts will also be presented on June 10, detailing the economic burden of these diseases in the U.S. Exa-cel is being investigated as a one-time therapy for these patients.

CRISPR Therapeutics (Nasdaq: CRSP) will host an Innovation Day on June 21, 2022, at 2:00 PM ET, focusing on its advanced research in genetic engineering and cell therapy. The event will showcase the company's innovative platform technologies and new discovery programs. A live webcast will be available on the company's website, with the recording archived for 30 days post-event. CRISPR Therapeutics is committed to developing transformative gene-based medicines targeting serious diseases, leveraging its proprietary CRISPR/Cas9 technology.

CRISPR Therapeutics (Nasdaq: CRSP) has appointed Dr. Phuong Khanh (P.K.) Morrow as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings over a decade of experience in global drug development, particularly in oncology, and will oversee the company's clinical development and regulatory operations. The leadership change aims to enhance CRISPR’s innovative gene-editing therapies. CEO Samarth Kulkarni emphasized her expertise will be essential in advancing their clinical strategy and building the organization.

CRISPR Therapeutics (Nasdaq: CRSP) announced that an abstract detailing safety and efficacy data from the ongoing CTX130 clinical trial for T-cell lymphoma has been accepted for oral presentation at the EHA 2022 Hybrid Congress, taking place June 9-12, 2022. This marks the first presentation of clinical data from the CTX130 program. The abstract, titled The COBALT-LYM Study of CTX130, will be presented by Dr. Swaminathan P. Iyer on June 11, 2022. CTX130 is a gene-edited CAR-T therapy targeting CD70, being investigated in two Phase 1 trials for relapsed/refractory malignancies.

CRISPR Therapeutics (CRSP) reported Q1 2022 financial results, highlighting significant progress in clinical trials. Key milestones include dosing over 75 patients with CTX001 in ongoing Phase 3 trials for beta thalassemia and sickle cell disease, with global regulatory submissions anticipated in late 2022. R&D expenses rose to $118.2 million, reflecting ongoing advancements in its immuno-oncology pipeline. Cash reserves stood at $2.22 billion, down from $2.38 billion in Q4 2021. Net loss for the quarter was $179.2 million, compared to $113.2 million a year prior.

CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management team will participate in the 2022 Bank of America Healthcare Conference on May 11, 2022, at 4:40 p.m. PT. A live webcast will be available on the Company's Investors section of the website, with a replay accessible for 14 days post-event. The company focuses on gene-based medicines to tackle serious diseases using its innovative CRISPR/Cas9 platform. CRISPR Therapeutics operates in multiple therapeutic areas, including oncology and rare diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.